Lab
Eurofins Ascend Clinical, LLC
Eurofins Ascend Clinical, LLC was paid $16.99M by Medicaid between Jan 2018 and Nov 2024, across 87 billing codes. Its largest line is 83970, — 25% of everything it billed.
33Billing provider infoEUROFINS ASCEND CLINICAL, LLC
SUNNYVALE, CA 94085
SUNNYVALE, CA 94085
33aNPI1982606992assigned 08/10/2005
33bProvider typeClinical Medical Laboratory
28Total paid$16.99M
24GClaims3,079,822
24DCodes billed87
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#53 of 561
Median peer was paid$222K
This provider vs. median77×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 285,402 | $1.53M | |
| 2019 | 361,735 | $1.95M | |
| 2020 | 429,810 | $2.43M | |
| 2021 | 531,540 | $3.28M | |
| 2022 | 513,839 | $2.69M | |
| 2023 | 555,490 | $2.96M | |
| 2024incomplete | 402,006 | $2.15M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 83970 | 25% | 155,273 | 138,552 | $4.24M | |
| 84466 | 8.5% | 174,782 | 155,242 | $1.44M | |
| 82728 | 7.2% | 136,368 | 121,975 | $1.23M | |
| 87340 | 5.8% | 134,054 | 121,489 | $984K | |
| 83540 | 4.6% | 174,816 | 155,123 | $775K | |
| 86769 | 4.2% | 37,757 | 21,905 | $711K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.5% | 31,915 | 28,258 | $428K |
| 86803 | 2.4% | 68,525 | 61,723 | $401K | |
| 84100 | 2.2% | 131,933 | 94,168 | $381K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.1% | 83,216 | 72,315 | $354K |
| 82108 | 2.1% | 23,565 | 21,630 | $352K | |
| 84520 | 2.1% | 167,165 | 78,040 | $349K |
75 more codes
| 86706 | 1.9% | 43,894 | $319K | |
| 80053 | Comprehensive metabolic panel | 1.9% | 39,755 | $318K |
| 80051 | 1.6% | 26,183 | $270K | |
| 84295 | 1.4% | 83,705 | $241K | |
| 82040 | 1.4% | 65,298 | $234K | |
| 85045 | 1.4% | 82,607 | $233K | |
| 84460 | 1.3% | 179,113 | $225K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.3% | 57,325 | $217K |
| 82310 | 1.3% | 75,585 | $213K | |
| 82947 | 1.2% | 199,052 | $209K | |
| 83735 | 1.2% | 44,533 | $201K | |
| 84132 | 1.1% | 68,268 | $195K | |
| 82247 | 1.1% | 124,779 | $191K | |
| 86704 | <1% | 20,611 | $166K | |
| 80061 | Lipid panel | <1% | 36,286 | $163K |
| 85018 | <1% | 94,436 | $149K | |
| 84075 | <1% | 49,520 | $147K | |
| 80069 | <1% | 19,298 | $129K | |
| 82746 | <1% | 13,846 | $122K | |
| 82607 | <1% | 13,379 | $114K | |
| 82565 | <1% | 40,175 | $112K | |
| 84450 | <1% | 52,848 | $107K | |
| 85027 | <1% | 21,801 | $106K | |
| 84155 | <1% | 48,182 | $98K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,980 | $93K |
| 84134 | <1% | 8,905 | $86K | |
| 85014 | <1% | 48,485 | $74K | |
| 87522 | Neg quan hep c or qual rna | <1% | 2,899 | $52K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,303 | $51K |
| 82570 | <1% | 12,304 | $43K | |
| 82374 | <1% | 20,796 | $43K | |
| 84630 | <1% | 5,697 | $39K | |
| 82435 | <1% | 16,236 | $38K | |
| 83615 | <1% | 18,008 | $34K | |
| 87040 | <1% | 7,010 | $34K | |
| 87521 | Neg quan hep c or qual rna | <1% | 2,111 | $31K |
| 84550 | <1% | 23,748 | $28K | |
| 83718 | <1% | 4,560 | $25K | |
| 82945 | <1% | 14,108 | $23K | |
| 82977 | <1% | 1,845 | $21K | |
| 84540 | <1% | 6,575 | $20K | |
| 82248 | <1% | 18,360 | $18K | |
| 80202 | <1% | 3,560 | $15K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,306 | $15K |
| 87186 | <1% | 2,479 | $10K | |
| 82330 | <1% | 885 | $9K | |
| 87077 | <1% | 2,473 | $8K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,549 | $7K |
| 82575 | <1% | 1,337 | $7K | |
| 82465 | <1% | 7,029 | $7K | |
| 84545 | <1% | 1,164 | $4K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 134 | $4K |
| 84478 | <1% | 3,775 | $4K | |
| 84153 | <1% | 287 | $3K | |
| 85610 | <1% | 2,531 | $3K | |
| 87071 | <1% | 1,262 | $3K | |
| 87070 | <1% | 769 | $3K | |
| 89051 | <1% | 1,155 | $3K | |
| 86140 | <1% | 2,189 | $2K | |
| 86705 | <1% | 414 | $2K | |
| 82379 | <1% | 183 | $2K | |
| 80076 | <1% | 416 | $2K | |
| 84156 | <1% | 1,684 | $2K | |
| 86703 | <1% | 569 | $1K | |
| 85049 | <1% | 583 | $1K | |
| 87015 | <1% | 417 | $1K | |
| 87205 | <1% | 435 | $826.60 | |
| 86592 | <1% | 131 | $251.31 | |
| 87075 | <1% | 35 | $244.29 | |
| 84436 | <1% | 62 | $207.83 | |
| 87350 | <1% | 34 | $195.74 | |
| 82274 | <1% | 126 | $180.77 | |
| 86709 | <1% | 13 | $129.99 | |
| 84439 | <1% | 42 | $79.18 | |
| 82747 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHUNSADER, PATRICIA (PRESIDENT)